Stephen Wright

Summary

Publications

  1. pmc Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach
    Stephen Wright
    GW Pharma, Ltd, Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, UK
    Trials 13:189. 2012
  2. ncbi request reprint Cannabinoid-based medicines for neurological disorders--clinical evidence
    Stephen Wright
    GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wilts, UK
    Mol Neurobiol 36:129-36. 2007

Collaborators

Detail Information

Publications2

  1. pmc Assessment of blinding to treatment allocation in studies of a cannabis-based medicine (Sativex®) in people with multiple sclerosis: a new approach
    Stephen Wright
    GW Pharma, Ltd, Porton Down Science Park, Salisbury, Wiltshire, SP4 0JQ, UK
    Trials 13:189. 2012
    ..We report the results of an evidence-based statistical approach to exploring the possible impact of unblinding to a cannabis-based medicine (Sativex®) in people with muscle spasticity due to multiple sclerosis...
  2. ncbi request reprint Cannabinoid-based medicines for neurological disorders--clinical evidence
    Stephen Wright
    GW Pharmaceuticals, Porton Down Science Park, Salisbury, Wilts, UK
    Mol Neurobiol 36:129-36. 2007
    ..One of these, Sativex (GW Pharmaceuticals), was approved as a prescription medicine in Canada in 2005 and is currently under regulatory review in the EU...